CN1642926A - 结晶帕瑞考昔钠 - Google Patents

结晶帕瑞考昔钠 Download PDF

Info

Publication number
CN1642926A
CN1642926A CNA038060884A CN03806088A CN1642926A CN 1642926 A CN1642926 A CN 1642926A CN A038060884 A CNA038060884 A CN A038060884A CN 03806088 A CN03806088 A CN 03806088A CN 1642926 A CN1642926 A CN 1642926A
Authority
CN
China
Prior art keywords
parecoxib sodium
parecoxib
feature
sodium
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038060884A
Other languages
English (en)
Chinese (zh)
Inventor
A·Y·希克
T·R·博哈特
L·J·费罗
G·D·丹泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of CN1642926A publication Critical patent/CN1642926A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA038060884A 2002-03-15 2003-03-12 结晶帕瑞考昔钠 Pending CN1642926A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US60/364,567 2002-03-15
US41798702P 2002-10-11 2002-10-11
US60/417,987 2002-10-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN 200710084349 Division CN101037419A (zh) 2002-03-15 2003-03-12 结晶帕瑞考昔钠
CN 200710084348 Division CN101037418A (zh) 2002-03-15 2003-03-12 结晶帕瑞考昔钠

Publications (1)

Publication Number Publication Date
CN1642926A true CN1642926A (zh) 2005-07-20

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038060884A Pending CN1642926A (zh) 2002-03-15 2003-03-12 结晶帕瑞考昔钠

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN117003769A (zh) * 2023-07-11 2023-11-07 宁波慈溪生物医学工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238669A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
WO2005065684A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英（江苏）药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英（江苏）药业有限公司 一种帕瑞昔布钠冻干粉针制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT892791E (pt) * 1996-04-12 2003-06-30 Searle & Co N-¬¬4-(5-metil-3-fenilisoxazol-4-il|fenil|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
KR20000049138A (ko) * 1996-10-15 2000-07-25 윌리암스 로저 에이 신생물의 치료 및 예방에의 시클로옥시게나제-2 저해제의 사용방법
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
KR20040085135A (ko) * 2001-10-02 2004-10-07 파마시아 코포레이션 벤젠설포닐 화합물의 제조 방법

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN117003769A (zh) * 2023-07-11 2023-11-07 宁波慈溪生物医学工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
MY148518A (en) 2013-04-30
CO5631437A2 (es) 2006-04-28
JP2005529084A (ja) 2005-09-29
KR20040095288A (ko) 2004-11-12
WO2003078408A1 (en) 2003-09-25
RU2300529C2 (ru) 2007-06-10
AR038985A1 (es) 2005-02-02
CA2478500A1 (en) 2003-09-25
KR100763045B1 (ko) 2007-10-04
MXPA04008932A (es) 2004-11-26
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
AU2003220180A1 (en) 2003-09-29
NZ535951A (en) 2006-02-24
TW200400949A (en) 2004-01-16
EP1485362A1 (en) 2004-12-15
US20030232871A1 (en) 2003-12-18
BR0308431A (pt) 2005-01-18

Similar Documents

Publication Publication Date Title
TW542836B (en) Pyrazolopyridine derivatives
TWI330639B (en) Oxazole compound and pharmaceutical composition
TWI597282B (zh) ６，７-不飽合-７-胺甲醯基嗎啡喃衍生物之結晶及其製造方法
JP6386478B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１ｈ−ピラゾロ［３，４−ｂ］ピリジノ−３−イル］ピリミジノ−５−イル｝メチルカルバメートの形態
CN1642926A (zh) 结晶帕瑞考昔钠
TW201311658A (zh) 有益於治療關節炎之新穎咪唑衍生物
JP2002535401A (ja) （ｓ）−オメプラゾールのカリウム塩
EP3162801B1 (en) Salt of halogen-substituted heterocyclic compound
WO2015014315A1 (zh) 一种抑制剂的晶型及其制备方法和用途
WO2014023104A1 (zh) 具有黄嘌呤氧化酶抑制活性的化合物及其盐、制备方法和用途
TW201036951A (en) Quinazolinone derivatives useful as vanilloid antagonists
JP2002543075A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
WO2019158051A1 (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
JP2025131661A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2000506876A (ja) ２―（３ｈ）―オキサゾロン誘導体およびｃｏｘ―２阻害剤としてのそれらの使用
CN1711247A (zh) 塞来考昔的前药
TW201002654A (en) Solid states of aliskiren free base
HK1075049A (en) Crystalline parecoxib sodium
CA2856100C (en) Nitrogen-containing fused ring compounds as crth2 antagonists
HK1106528A (en) Crystalline parecoxib sodium
HK1106529A (en) Crystalline parecoxib sodium
WO2011162300A1 (ja) 縮合ピリジン化合物塩の結晶
CN101037418A (zh) 结晶帕瑞考昔钠
JPWO2004101551A1 (ja) ベンズイミダゾール誘導体の結晶及びその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075049

Country of ref document: HK

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075049

Country of ref document: HK